BOSTON, Nov. 03, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced that corporate presentations would be delivered at the following upcoming investor conferences.
Credit Suisse 24th Annual Healthcare Conference
Presenter: Greg Madison, Chief Executive Officer
Presentation Date: Tuesday, November 10, 2015
Presentation Time: 10:00 a.m. MST (12:00 p.m. EST)
Stifel 2015 Healthcare Conference
Presenter: Greg Madison, Chief Executive Officer
Presentation Date: Tuesday, November 17, 2015
Presentation Time: 11:00 a.m. EST
Live audio webcasts of these presentations will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under the “webcasts and presentations” page. Archived versions of these webcasts will be available for at least 15 days following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, with offices in New York and Boston, is focused on bringing innovative therapies to market for patients with renal disease. In December 2014, the company launched its first FDA-approved product, Auryxia™ (ferric citrate) for the control of elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on dialysis, in the United States. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex) for the control of hyperphosphatemia in adults with non-dialysis and dialysis-dependent chronic kidney disease. For more information about Keryx, please visit www.keryx.com.